PL1921146T3 - Rekombinowane wektory oparte na zmodyfikowany wirusie ankara (mva) jako profilaktyczne i terapeutyczne szczepionki przeciw aids - Google Patents
Rekombinowane wektory oparte na zmodyfikowany wirusie ankara (mva) jako profilaktyczne i terapeutyczne szczepionki przeciw aidsInfo
- Publication number
- PL1921146T3 PL1921146T3 PL06778467T PL06778467T PL1921146T3 PL 1921146 T3 PL1921146 T3 PL 1921146T3 PL 06778467 T PL06778467 T PL 06778467T PL 06778467 T PL06778467 T PL 06778467T PL 1921146 T3 PL1921146 T3 PL 1921146T3
- Authority
- PL
- Poland
- Prior art keywords
- mva
- preventive
- recombinant vectors
- vectors based
- vaccines against
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 229940021747 therapeutic vaccine Drugs 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- C12N15/8636—Vaccina virus vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200501841A ES2281252B1 (es) | 2005-07-27 | 2005-07-27 | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
ES200600762A ES2282041B1 (es) | 2005-07-27 | 2006-03-24 | Mejoras introducidas en el objeto de la patente principal n es200501841 para "vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida". |
EP06778467A EP1921146B1 (en) | 2005-07-27 | 2006-07-25 | Recombinant vectors based on the modified ankara virus (mva) as preventive and therapeutic vaccines against aids |
PCT/ES2006/070114 WO2007012691A1 (es) | 2005-07-27 | 2006-07-25 | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapéuticas contra el sida |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1921146T3 true PL1921146T3 (pl) | 2013-01-31 |
Family
ID=38458314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06778467T PL1921146T3 (pl) | 2005-07-27 | 2006-07-25 | Rekombinowane wektory oparte na zmodyfikowany wirusie ankara (mva) jako profilaktyczne i terapeutyczne szczepionki przeciw aids |
Country Status (8)
Country | Link |
---|---|
US (1) | US8871219B2 (pl) |
EP (1) | EP1921146B1 (pl) |
CY (1) | CY1113288T1 (pl) |
DK (1) | DK1921146T3 (pl) |
ES (3) | ES2281252B1 (pl) |
PL (1) | PL1921146T3 (pl) |
PT (1) | PT1921146E (pl) |
WO (1) | WO2007012691A1 (pl) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2047861B1 (en) * | 2007-10-12 | 2019-07-31 | Institut Pasteur | Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications |
CN102083462B (zh) | 2007-08-03 | 2015-02-18 | 巴斯德研究院 | 慢病毒基因转移载体及其医学应用 |
WO2010029260A1 (fr) * | 2008-09-10 | 2010-03-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Construction d'un gène synthétique codant pour gag de vih1 et son utilisation pour obtention de vaccins anti-vih-1 |
JP2013507107A (ja) | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Hivに対するヒトにおける広範なt細胞応答の生成 |
AP2012006258A0 (en) * | 2009-10-13 | 2012-06-30 | Geovax Inc | Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens. |
MX350795B (es) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
EP2755684A1 (en) | 2011-09-12 | 2014-07-23 | Jonathan Norden Weber | Methods and compositions for raising an immune response to hiv |
AU2016229408A1 (en) | 2015-02-25 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
WO2016168862A1 (en) | 2015-04-17 | 2016-10-20 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
US11278607B2 (en) | 2016-01-08 | 2022-03-22 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
JP7454645B2 (ja) * | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ, インコーポレイテッド | Hivワクチン並びにその作製方法及び使用方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220276A1 (en) * | 1995-05-16 | 2003-11-27 | Opendra Narayan | HIV vaccine and method of use |
CA2369119A1 (en) * | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
AP1674A (en) * | 1999-11-16 | 2006-10-30 | Geneart Ag | The genome of the HIV-1 inter-subtype (C/B') and use thereof. |
EP1156112B1 (en) * | 2000-05-18 | 2006-03-01 | Geneart GmbH | Synthetic gagpol genes and their uses |
WO2002032943A2 (en) * | 2000-08-14 | 2002-04-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
ES2334335T3 (es) * | 2001-03-08 | 2010-03-09 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Mva que expresa genes de envoltura, gag y pol de vih modificados. |
GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
CN1490056A (zh) | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
EP1610816B1 (en) | 2003-03-28 | 2013-01-02 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mva virus expressing modified hiv envelope, gag, and pol genes |
AU2004279362B2 (en) * | 2003-09-15 | 2011-03-17 | Genvec, Inc. | HIV vaccines based on ENV of multiple clades of HIV |
US20090214588A1 (en) * | 2004-07-16 | 2009-08-27 | Nabel Gary J | Vaccines against aids comprising cmv/r-nucleic acid constructs |
-
2005
- 2005-07-27 ES ES200501841A patent/ES2281252B1/es not_active Expired - Fee Related
-
2006
- 2006-03-24 ES ES200600762A patent/ES2282041B1/es not_active Expired - Fee Related
- 2006-07-25 EP EP06778467A patent/EP1921146B1/en not_active Not-in-force
- 2006-07-25 PT PT06778467T patent/PT1921146E/pt unknown
- 2006-07-25 DK DK06778467.8T patent/DK1921146T3/da active
- 2006-07-25 US US11/989,425 patent/US8871219B2/en not_active Expired - Fee Related
- 2006-07-25 ES ES06778467T patent/ES2392670T3/es active Active
- 2006-07-25 WO PCT/ES2006/070114 patent/WO2007012691A1/es active Application Filing
- 2006-07-25 PL PL06778467T patent/PL1921146T3/pl unknown
-
2012
- 2012-10-19 CY CY20121100989T patent/CY1113288T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2282041A1 (es) | 2007-10-01 |
US20100047276A1 (en) | 2010-02-25 |
ES2281252A1 (es) | 2007-09-16 |
CY1113288T1 (el) | 2016-04-13 |
DK1921146T3 (da) | 2012-11-05 |
US8871219B2 (en) | 2014-10-28 |
PT1921146E (pt) | 2012-11-12 |
EP1921146B1 (en) | 2012-08-01 |
ES2281252B1 (es) | 2009-02-16 |
WO2007012691A1 (es) | 2007-02-01 |
ES2282041B1 (es) | 2009-03-16 |
ES2392670T3 (es) | 2012-12-12 |
EP1921146A1 (en) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1921146T3 (pl) | Rekombinowane wektory oparte na zmodyfikowany wirusie ankara (mva) jako profilaktyczne i terapeutyczne szczepionki przeciw aids | |
IL261346A (en) | Tissue protective peptides and their uses | |
IL191595A0 (en) | Stabilizing formulations for recombinant viruses | |
AP2351A (en) | Improved adenoviral vectors and uses thereof. | |
ZA200703838B (en) | Multivalent vaccines comprising recombinant viral vectors | |
SI1673460T1 (sl) | Rekombinantna cepiva in njihova uporaba | |
EP1751179A4 (en) | PEPTIDES DERIVED FROM THE CASEIN AND THEIR THERAPEUTIC USES | |
AU2003295502A8 (en) | Adenoviral vector vaccine | |
EP1875344A4 (en) | SYSTEM AND METHOD FOR ADVANCED PROTECTION AND CONTROL THROUGH THE USE OF AN IDENTITY | |
GB0526211D0 (en) | Viral vectors | |
AU2003288273A8 (en) | New settings for recombinant adenoviral-based vaccines | |
HK1124868A1 (en) | Truncated human papillomavirus type 16 l1 proteins | |
IL208070A0 (en) | Myxoma virus mutants for therapeutic treatment | |
EP1893233A4 (en) | PEPTIDES AND THERAPEUTIC VACCINES | |
AU2003289223A1 (en) | Highly safe smallpox vaccine virus and vaccinia virus vector | |
EP1718330A4 (en) | COMPLEX POLYPEPTIDE AND ADJUVANT FOR ENHANCED VACCINES | |
PL1762219T3 (pl) | Fotoochronne i/lub fotoimmunoochronne kompozycje do skóry i ich zastosowania | |
EP2114459A4 (en) | RECOMBINANT VIRAL VECTORS FOR PREVENTION AND PROTECTION AGAINST ALPHAVIRUS INFECTION | |
GB0517293D0 (en) | Vectors and uses thereof | |
EP1829969A4 (en) | NOVEL POLYPEPTIDE AND USE THEREOF | |
IL213318A0 (en) | C1orf59 peptides and vaccines including the same | |
IL180839A0 (en) | Vaccine comprising recombinant ct or lt toxin | |
EP1833989A4 (en) | VIRUS PREPARATIONS AND METHODS | |
ZA200800566B (en) | Therapeutic peptides and vaccines | |
EP1934608A4 (en) | TARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDES |